OVER A DECADE OF STUDIES IN BIPOLAR DISORDER HIGH RISK POPULATIONS: WHAT HAVE WE LEARNT AND WHAT ARE THE GAPS?

IF 6.1 2区 医学 Q1 CLINICAL NEUROLOGY
Philip Mitchell (Chair) , John Nurnberger (Co-chair) , Fernando Goes (Discussant)
{"title":"OVER A DECADE OF STUDIES IN BIPOLAR DISORDER HIGH RISK POPULATIONS: WHAT HAVE WE LEARNT AND WHAT ARE THE GAPS?","authors":"Philip Mitchell (Chair) ,&nbsp;John Nurnberger (Co-chair) ,&nbsp;Fernando Goes (Discussant)","doi":"10.1016/j.euroneuro.2024.08.018","DOIUrl":null,"url":null,"abstract":"<div><div>Bipolar disorder (BD) is a highly familial condition, with a heritability of at least 70%, and with10-15% of first-degree relatives developing this illness. Unlike schizophrenia, there is no distinct prodromal (ultra high-risk) syndrome, making development of early intervention treatment programs difficult. Studies of high-risk young people with a family history of BD provide the potential for identifying clinical and/or biological changes that either predate or occur early in the development of BD, thereby presenting targets for early intervention therapies. This symposium will focus on what has been learnt from over a decade of BD high-risk studies globally, and what remains unknown or uncertain. Speakers will address these issues from both their own cohorts and the field more broadly. This symposium will comprise presentations by:<ul><li><span>i)</span><span><div>John Nurnberger - Emeritus Professor, University of Indiana, USA. He led the NIMH Genetics Initiative Bipolar Group. His group has been active in the Bipolar Genome Study Consortium and in the Psychiatric Genomics Consortium. He established the US BD high-risk consortium, with sites at the universities of Indianapolis and Michigan, as well as Johns Hopkins University;</div></span></li><li><span>ii)</span><span><div>Janice Fullerton - Principal Research Scientist at Neuroscience Research Australia and Conjoint Associate Professor, University of New South Wales in Sydney, Australia. Jan will present genetics and neuroimaging data from the Australian Bipolar Kids and Sibs high-risk cohort;</div></span></li><li><span>iii)</span><span><div>Kathryn Freeman is a Research Assistant on the FORBOW Project, and PhD Student in Medical Neuroscience at Dalhousie University, Canada. Kate will present on bipolar disorder offspring findings from the FORBOW study; and</div></span></li><li><span>iv)</span><span><div>Philip Mitchell - Professor of Psychiatry at the University of New South Wales in Sydney who established the Australian Bipolar Kids and Sibs high-risk cohort. He will present findings from the 10-year follow-up of this sample.</div></span></li></ul></div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"87 ","pages":"Page 5"},"PeriodicalIF":6.1000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Neuropsychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0924977X24002177","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Bipolar disorder (BD) is a highly familial condition, with a heritability of at least 70%, and with10-15% of first-degree relatives developing this illness. Unlike schizophrenia, there is no distinct prodromal (ultra high-risk) syndrome, making development of early intervention treatment programs difficult. Studies of high-risk young people with a family history of BD provide the potential for identifying clinical and/or biological changes that either predate or occur early in the development of BD, thereby presenting targets for early intervention therapies. This symposium will focus on what has been learnt from over a decade of BD high-risk studies globally, and what remains unknown or uncertain. Speakers will address these issues from both their own cohorts and the field more broadly. This symposium will comprise presentations by:
  • i)
    John Nurnberger - Emeritus Professor, University of Indiana, USA. He led the NIMH Genetics Initiative Bipolar Group. His group has been active in the Bipolar Genome Study Consortium and in the Psychiatric Genomics Consortium. He established the US BD high-risk consortium, with sites at the universities of Indianapolis and Michigan, as well as Johns Hopkins University;
  • ii)
    Janice Fullerton - Principal Research Scientist at Neuroscience Research Australia and Conjoint Associate Professor, University of New South Wales in Sydney, Australia. Jan will present genetics and neuroimaging data from the Australian Bipolar Kids and Sibs high-risk cohort;
  • iii)
    Kathryn Freeman is a Research Assistant on the FORBOW Project, and PhD Student in Medical Neuroscience at Dalhousie University, Canada. Kate will present on bipolar disorder offspring findings from the FORBOW study; and
  • iv)
    Philip Mitchell - Professor of Psychiatry at the University of New South Wales in Sydney who established the Australian Bipolar Kids and Sibs high-risk cohort. He will present findings from the 10-year follow-up of this sample.
十多年来对躁狂症高危人群的研究:我们学到了什么,还有哪些不足?
躁郁症(BD)是一种高度家族性疾病,遗传率至少为 70%,10%-15% 的一级亲属会患上这种疾病。与精神分裂症不同,躁郁症没有明显的前驱期(超高危)综合征,因此很难制定早期干预治疗方案。对有 BD 家族史的高危青少年进行研究,有可能发现 BD 发病前或发病早期的临床和/或生物学变化,从而为早期干预治疗提供目标。本次研讨会将重点讨论十多年来全球范围内开展的BD高风险研究的成果,以及仍存在的未知或不确定因素。发言者将从各自的队列和更广泛的领域来探讨这些问题。本次研讨会将包括以下演讲:i) John Nurnberger - 美国印第安纳大学名誉教授。他领导了美国国立卫生研究院遗传学计划躁郁症小组。他领导的小组一直活跃在双相情感基因组研究联盟和精神病基因组学联盟中。他建立了美国躁郁症高风险联盟,在印第安纳波利斯大学、密歇根大学和约翰霍普金斯大学设立了研究基地;ii) Janice Fullerton - 澳大利亚神经科学研究中心首席研究科学家,澳大利亚悉尼新南威尔士大学联合副教授。Jan 将介绍澳大利亚躁郁症儿童和兄弟姐妹高危人群的遗传学和神经影像学数据;iii)Kathryn Freeman 是 FORBOW 项目的研究助理,也是加拿大达尔豪西大学医学神经科学专业的博士生。凯特将介绍FORBOW研究中关于双相情感障碍后代的发现;iv)菲利普-米切尔(Philip Mitchell)--悉尼新南威尔士大学精神病学教授,他建立了澳大利亚双相情感障碍儿童和兄弟姐妹高风险队列。他将介绍对该样本进行 10 年跟踪调查的结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
European Neuropsychopharmacology
European Neuropsychopharmacology 医学-精神病学
CiteScore
10.30
自引率
5.40%
发文量
730
审稿时长
41 days
期刊介绍: European Neuropsychopharmacology is the official publication of the European College of Neuropsychopharmacology (ECNP). In accordance with the mission of the College, the journal focuses on clinical and basic science contributions that advance our understanding of brain function and human behaviour and enable translation into improved treatments and enhanced public health impact in psychiatry. Recent years have been characterized by exciting advances in basic knowledge and available experimental techniques in neuroscience and genomics. However, clinical translation of these findings has not been as rapid. The journal aims to narrow this gap by promoting findings that are expected to have a major impact on both our understanding of the biological bases of mental disorders and the development and improvement of treatments, ideally paving the way for prevention and recovery.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信